Genentech releases one-year Phase III data on vamikibart for UME

Genentech, a member of the Roche Group, announced new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart versus a sham procedure that mimics intravitreal injections in adults with uveitic macular edema (UME).